Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates

British Journal of Haematology
Kirstin LundRobert Campbell Tait

Abstract

Poor warfarin control with resultant high International Normalized Ratios (INRs) and bleeding events is most common during the first months of treatment. The effects of genetic polymorphisms at the vitamin K epoxide reductase [VKORC1] and cytochrome P450 2C9 [CYP2C9] loci have been increasingly acknowledged as contributory factors of enhanced warfarin sensitivity. In our prospective, blinded study, 557 patients (49·1% male, mean age 65·4 years, range 18-91 years) commencing warfarin (target INR 2·5) were genotyped and monitored through the first 3 months of anticoagulation. Homozygosity for the -1639 G>A single nucleotide functional promoter polymorphism of the VKORC1 gene (genotype AA; 14·5% of cases) was associated with a significantly shortened time to therapeutic INR ≥ 2 (P < 0·01), reduced stable warfarin dose (P < 0·01), and an increased number of INRs > 5 (P < 0·001) and occurrence of bleeding events (P < 0·01) during the first month, as compared to the GG genotype. CYP2C9 genetic variations *2 and *3 were not associated with significant effect on these factors. Neither VKORC1 nor CYP2C9 polymorphisms influenced these parameters beyond the first month of treatment. These findings imply possible benefits of assessing VKOR...Continue Reading

References

Apr 28, 1984·British Medical Journal·A FennertyP A Routledge
Jun 20, 1998·British Journal of Haematology·R C Tait, A Sefcick
Sep 2, 1998·British Journal of Clinical Pharmacology·A OatesK S Channer
Sep 12, 1998·British Journal of Haematology·M Bhavnani, K H Shwe
Jan 12, 2000·Australian and New Zealand Journal of Medicine·G W RobertsV S Eaton
Apr 3, 2002·JAMA : the Journal of the American Medical Association·Mitchell K HigashiAllan E Rettie
Apr 21, 2005·Thrombosis and Haemostasis·Deepak VooraBrian F Gage
Apr 22, 2005·Journal of Thrombosis and Haemostasis : JTH·S SchulmanUNKNOWN Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on T
May 11, 2005·The Pharmacogenomics Journal·M WadeliusP Deloukas
Jun 3, 2005·The New England Journal of Medicine·Mark J RiederAllan E Rettie
Sep 15, 2005·Clinical Medicine & Research·Michael A HillmanJames K Burmester
Mar 28, 2007·Blood·Eric A MillicanBrian F Gage
Apr 26, 2007·Clinical Medicine & Research·Michael D CaldwellJames K Burmester
Aug 1, 2007·Journal of Thrombosis and Haemostasis : JTH·J OldenburgC R Müller
Nov 9, 2007·Circulation·Jeffrey L AndersonUNKNOWN Couma-Gen Investigators
Feb 19, 2008·Genetics in Medicine : Official Journal of the American College of Medical Genetics·David A FlockhartUNKNOWN ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use
Jul 17, 2008·Journal of Thrombosis and Haemostasis : JTH·S M ThackerB F Gage
Jul 17, 2008·Journal of Thrombosis and Haemostasis : JTH·P M MannucciF Peyvandi
Feb 21, 2009·The New England Journal of Medicine·UNKNOWN International Warfarin Pharmacogenetics ConsortiumJ A Johnson
Mar 24, 2009·Journal of General Internal Medicine·Kirsten Neudoerffer KangelarisJeffrey A Tice
Aug 19, 2009·Annals of Internal Medicine·Michael H Rosove, Wayne W Grody
Oct 31, 2009·Journal of Thrombosis and Haemostasis : JTH·N S FerderB F Gage
Mar 23, 2011·Genetics in Medicine : Official Journal of the American College of Medical Genetics·James K BurmesterMichael D Caldwell
Jun 16, 2011·British Journal of Haematology·David KeelingUNKNOWN British Committee for Standards in Haematology
Dec 7, 2011·Circulation·John F Carlquist, Jeffrey L Anderson

❮ Previous
Next ❯

Citations

Jun 19, 2013·Journal of Thrombosis and Thrombolysis·Priccila ZuchinaliLuis E Rohde
Jun 13, 2014·Thrombosis and Haemostasis·E Jiménez-VaroM Á Calleja-Hernández
Aug 8, 2013·British Journal of Clinical Pharmacology·Talitha I VerhoefAnke-Hilse Maitland-van der Zee
Apr 11, 2015·Pharmacoepidemiology and Drug Safety·Joshua A RothDenise Boudreau
Dec 19, 2014·Pharmacogenomics·Vivian K KawaiC Michael Stein
Feb 8, 2014·Clinical Pharmacology and Therapeutics·J A RothD L Veenstra
Nov 20, 2016·Clinical Chemistry·Kevin FriedeDeepak Voora
Jun 4, 2016·ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs·Veli K TopkaraUlrich P Jorde
Sep 8, 2019·Scientific Reports·Zhiyuan MaKoroush Khalighi
Aug 24, 2017·Journal of Thrombosis and Haemostasis : JTH·M NaglerD Aujesky
Apr 7, 2018·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Ahmed M L BedewyLamia Saeed Kandil
Nov 10, 2018·European Journal of Clinical Pharmacology·Chanan ShaulYoseph Caraco
Jan 27, 2019·Chemistry : a European Journal·Hui XingCraig M Williams
Dec 15, 2020·Journal of Thrombosis and Haemostasis : JTH·Xuejie ChenJian-Ke Tie
May 31, 2019·Bioorganic & Medicinal Chemistry Letters·Hui XingCraig M Williams

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.